Association of the -160 C>A Polymorphism in the CDH1 Promoter with Gastric Cancer: A Case-control Study

Document Type: Research Article

Authors

1 Molecular & Cell Biology Research Lab 2, Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Mazandaran, Iran

2 Department of Toxicology, Faculty of Pharmacy, Mazandaran Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Abstract

E-cadherin is a tumor suppressor protein that plays a crucial role in cell-cell adherens junction and tissue architecture and it is hypothesized to participate in carcinogenesis. It has been shown that a polymorphism in the upstream of the transcription start site of the CDH1 gene affects E-cadherin transcriptional regulation and seems to be associated with a variety of cancers. For the first time, we investigated the association of the rs16260 in the 5'-untranslated region of the CDH1 gene with gastric cancer in Iranian population. Seventy- eight patients with gastric cancer and 72 healthy individuals were included and genotyped for this SNP using the PCR-RFLP method. Our results showed that the frequency of the AA genotype in gastric cancer patients (16 of 78, 20.5%) was higher than healthy individuals (9 of 72, 12.5%), the frequency of the A allele in the patients group was higher than controls (OR=1.231, 95% CI= 0.772-1.962, p-value= 0.383), but statistical analysis revealed the absence of association between AA genotype and gastric cancer risk (OR=1.719, 95% CI= 0.656-4.502, p-value= 0.268). In conclusion, our results suggest that this substitution and the AA genotype have not a major impact on the individual’s susceptibility to gastric cancer, and therefore this SNP may be an ethnicity-dependent risk factor. Further works with larger sample size and including other criteria such as H. pylori infection status are needed for more accuracy.

Keywords


Al-Moundhri MS, Al-Khanbashi Ml, Al-Kindi M, Al-Nabhani M, Burney IA, Al-Farsi A, Al-Bahrani B. 2010. Association of E-cadherin (CDH1) gene polymorphisms and gastric cancer risk. World J Gastrointest Oncol 16: 3432-3436.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394-424.

Borges BDN, Santos EDS, Bastos CEMC, Pinto LC, Anselmo NP, Quaresma JAS, Calcagno DQ, Burbano RMR, Harada ML. 2010. Promoter polymorphisms and methylation of E-cadherin (CDH1) and KIT in gastric cancer patients from northern Brazil. Anticancer Res 30(6): 2225-2234.

Cattaneo F, Venesio T, Molatore S, Russo A, Fiocca R, Frattini M, Scovassi AI, Ottini L, Bertario L, Ranzani GN. 2006. Functional analysis and case-control study of –160C/A polymorphism in the E-cadherin gene promoter: Association with cancer risk. Anticancer Res 26: 4627-4632.

Carcas LP. 2014. Gastric cancer review. J Carcinog 13: 14. doi: 10.4103/1477-3163.146506.

Chen B, Zhou Y, Yang P, Liu L, Qin XP, Wu XT. 2011. CDH1 -160C>A gene polymorphism is an ethnicity-dependent risk factor for gastric cancer. Cytokine 55: 266-273.

Chu CM, Chen CJ, Chan DC, Wu HS, Liu YC, Shen CY, Chang TM, Yu J, Harn HJ, Yu CP, YangMH. 2014. CDH1 polymorphisms and haplotypes in sporadic diffuse and intestinal gastric cancer: a case–control study based on direct sequencing analysis. World J Surg Oncol 12: 80. doi: 10.1186/1477-7819-12-80.

Corso G, Roviello F, Paredes J, Pedrazzani C, Novais M, Correia J, Marrelli D, Cirnes L, Seruca R, Oliveira C, Suriano G. 2007. Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. Eur J Surg Oncol 33: 1061-1067.Lu Y, Lu F, Zeng S, Sun S,

Deng N, Zhou H, Fan H, Yuan Y. 2017. Single nucleotide polymorphisms and cancer susceptibility. Oncotarget 8: 110635-110649.

El-Husny A, Raiol-Moraes M, Amador M, Ribeiro-dos-Santos AM, Montagnini A, Barbosa S, Silva A, Assumpção P, Ishak G, Santos S, Pinto P, Cruz A, Ribeiro-dos-Santos Â. 2016.  CDH1 mutations in gastric cancer patients from northern Brazil identified by next-generation sequencing (NGS). Genet Mol Biol 39: 189-198.

Forszt P, Pilecka A, Malodobra M, Markowsk J, Maksymowicz K, Dobosz T. 2009. Single-nucleotide polymorphism association study of VDR and CDH1 genes and the risk of prostate cancer. Adv Clin Exp Med 18: 215-220.

Gao L, Nieters A, Brenner H. 2008. Meta-analysis: tumour invasion-related genetic polymorphisms and gastric cancer susceptibility. Aliment Pharmacol Ther 28(5):565-573.

Geng P, Chen Y, Ou J, Yin X, Sa R, Liang H. 2012. The E-cadherin (CDH1) -C160A polymorphism and colorectal cancer susceptibility: A meta-analysis. DNA Cell Biol 31: 1070-1077.

Humar B, Graziano F, Cascinu S, Catalano V, Ruzzo AM, Magnani M, Toro T, Burchill T, Futschik ME, Merriman T, Guilford P. 2002. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 21: 8192 – 8195.

Jiang B, Zhu K, Shao H, Bao C, Ou J, Sun W. 2015. Lack of association between the CDH1 polymorphism and gastric cancer susceptibility: a meta-analysis. Sci Rep 5: 7891-7897.

Kiemeney LA, Houwelingen KP, Bogaerts M, Witjes JA, Swinkels DW, Heijer M, Franke B, Schalken JA, Verhaegh GW. 2006. Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. Eur J of Cancer 42: 3219-3227.

Li G, Pan T, Guo D, Li LC. 2014. Regulatory variants and disease: The E-cadherin -160 C/A SNP as an example. Mol Biol Int 2014: 967565.

Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, Au HC, Nojima D, Carroll P, Dahiya R. 2000. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 60: 873-876.

Lu L, Liu L. 2015. Genetics and gastric cancer susceptibility. Int J Clin Exp Med 8: 8377-8383.

Lu Y, Xu YC, Shen J, Yu RB, Niu JY, Guo JT, Hu X, Shen HB. 2005. E-cadherin gene C-160A promoter polymorphism and risk of non-cardia gastric cancer in a Chinese population. World J Gastroenterol 11:56-60.

Ma J, Shen H, Kapesa L, Zeng S. 2016. Lauren classification and individualized chemotherapy in gastric cancer (Review). Oncol Lett 11: 2959-2964.

Memni H, Macherki Y, Klayech Z, Ben‑Haj‑Ayed A, Farhat K, Remadi Y, Gabbouj S, Mahfoudh W, Bouzid N, Bouaouina N, Chouchane L, Zakhama A, Hassen E. 2016. E-cadherin genetic variants predict survival outcome in breast cancer patients. J Transl Med 14:320-321.

Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. 2008. Loss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways. Cancer Res 68:3645-3654.

Pharoah PD, Guilford P, Caldas C. 2001. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121: 1348-1353.

Petrova YI, Schecterson L, Gumbiner BM. 2016. Roles for E-cadherin cell surface regulation in cancer. Mol Biol Cell 27(21): 3181-3375.

Pisignano G, Napoli S, Magistri M, Mapelli SN, Pastori C, Marco SD, Civenni G, Albino D, Enriquez C, Allegrini S, Mitra A, D’Ambrosio G, Mello-Grand M, Chiorino G, Garcia-Escudero R, Varani G, Carbone GM, Catapano CV. 2017. A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers. Nat Commun 8:15622.

Qiu LX, Li RT, Zhang JB, Zhong WZ, Bai JL, Liu BR, Zheng MH, Qian XP. 2009. The E-cadherin (CDH1) -160 C/A polymorphism and prostate cancer risk: a meta-analysis. Eur J Hum Genet 17: 244-249.

Qiu MZ, Cai MY, Zhang DS, Wang ZQ, Wang DS, Li YH, Xu RH. 2013. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med 11:58. doi:10.1186/1479-5876-11-58.

Shin Y, Kim IJ, Kang HC, Park JH, Park HR, Park HW, Park MA, Lee JS, Yoon KA, Ku JL, Park JG. 2004. The E-cadherin −347G→GA promoter polymorphism and its effect on transcriptional regulation. Carcinogenesis 25: 895-899.

Shokrzadeh M, Mohammadpour A, Tabari YS, Almani SP. 2017. Investigating the distribution of ERCC2 (rs13181) gene polymorphism in gastric cancer patients in Mazandaran: A case-control study. J Genet Resour 3: 54-60.

Suriano G, Mulholland D, de Wever O, Ferreira P, Mateus AR, Bruyneel E, Nelson CC, Mareel MM, Yokota J, Huntsman D, Seruca R. 2003. The intracellular E-cadherin germline mutation V832M lacks the ability to mediate cell–cell adhesion and to suppress invasion. Oncogene 22:5716–5719.

Tafrihy M, Mohammadzadeh R, Jahanzad E, Arab Najafi SM. 2007. Mutations in the β-catenin gene in gastric and esophageal cancers: an analysis in Iranian patients. JSUT 32: 161-167.

Tafrihi M, Nakhaei Sistani R. 2017. E-Cadherin/β-catenin complex: A target for anticancer and antimetastasis plants/plant-derived compounds. Nutr Cancer 69: 702-722. 

Tafrihi M, Toosi S, Minaei T, Gohari AR, Niknam V, Arab Najafi M. 2014. Anticancer properties of Teucrium persicum in PC-3 prostate cancer cells. Asian Pac J Cancer Prev 15: 785-791.

Ushijima T, Sasako M. 2004. Focus on gastric cancer. Cancer Cell 5: 121-126.

Wang L, Wang G, Lu C, Feng B, Kang J. 2012. Contribution of the -160 C/A polymorphism in the E-cadherin promoter to cancer risk: A meta-analysis of 47 case-control studies. PLoS ONE 7(7): e40219.

Wang Y, Yang H, Li L, Wang H, Zhang C, Xia X. 2012. E-cadherin (CDH1) gene promoter polymorphism and the risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis 27:151-158.

Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW. 2008. The E-cadherin gene polymorphism -160C/A and cancer risk: A HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol 167: 7-14.

Wong SHM, Fangb CM, Chuah LH, Leong CO, Ngai SC. 2018. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol 121:11-22.

Wu MS, Huang SP, Chang YT, Lin MT, Shun CT, Chang MC, Wang HP, Chen CJ, Lin JT. 2002. Association of the -160 C→A promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer 94: 1443-1448.

Zhang XF, Wang YM, Ge H, Cao YY, Chen ZF, Wen DG, Guo W, Wang N, Li Y, Zhang JH. 2008. Association of CDH1 single nucleotide polymorphisms with susceptibility to esophageal squamous cell carcinomas and gastric cardia carcinomas. Dis Esophagus 21: 21-29.

Zhao L, Wang YX, Xi M, Liu SL, Zhang P, Luo LL, Liu MZ. 2015. Association between E-cadherin (CDH1) polymorphisms and pancreatic cancer risk in Han Chinese population. Int J Clin Exp Pathol 8:5753-5760.